Literature DB >> 25454884

The ethics of disease eradication.

James Wilson1.   

Abstract

This paper provides an examination of the ethics of disease eradication policies. It examines three arguments that have been advanced for thinking that eradication is in some way ethically exceptional as a policy goal. These are (1) global eradication has symbolic importance, (2) disease eradication is a global public good and (3) disease eradication is a form of rescue. It argues that none of these provides a good reason to think that individuals have special duties to facilitate eradication campaigns, or that public health authorities have special permissions to pursue them. But the fact that these arguments fail does not entail that global disease eradication is ethically problematic, or that it should not be undertaken. Global eradication of a disease, if successful, is a way of providing an enormous health benefit that stretches far into the future. There is no need to reach for the idea that there is a special duty to eradicate disease; the same considerations that are in play in ordinary public health policy--of reducing the burden of disease equitably and efficiently--suffice to make global disease eradication a compelling goal where doing so is feasible.
Copyright © 2014 The Author. Published by Elsevier Ltd.. All rights reserved.

Keywords:  Eradication; Ethics; Global public goods; Symbolic value; Time discounting; Vaccination ethics

Mesh:

Year:  2014        PMID: 25454884     DOI: 10.1016/j.vaccine.2014.10.009

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age.

Authors:  Line M Lindgren; Pernille N Tingskov; Annette H Justesen; Bettina S Nedergaard; Klaus J Olsen; Lars V Andreasen; Ingrid Kromann; Charlotte Sørensen; Jes Dietrich; Birgit Thierry-Carstensen
Journal:  Vaccine       Date:  2016-12-24       Impact factor: 3.641

2.  Economic evaluation of disease elimination: An extension to the net-benefit framework and application to human African trypanosomiasis.

Authors:  Marina Antillon; Ching-I Huang; Kat S Rock; Fabrizio Tediosi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-14       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.